Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
2.080
+0.110 (+5.58%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss
↗
November 06, 2025
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.
Via
Chartmill
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
November 06, 2025
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
November 04, 2025
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
October 30, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
October 08, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
September 29, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
July 31, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 21, 2025
Via
Benzinga
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
July 17, 2025
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapy
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
July 15, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
June 26, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
June 17, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the 2025 BIO International Convention
June 11, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
May 01, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Research License with Catalent
April 15, 2025
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the Investival Showcase USA
March 06, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
March 05, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
February 20, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
February 05, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
January 23, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
